Aquestive therapeutics reports positive topline data for anaphylm™ (epinephrine) sublingual film from self-administration study

Warren, n.j., july 25, 2024 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst) (“aquestive” or the “company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today released positive topline pk data from the self-administration study of anaphylm™ (epinephrine) sublingual film. anaphylm has the potential to be the first and only non-invasive, orally delivered epinephrine for the treatment of severe life-threatening allergic reactions, including anaphylaxis, if approved by the united states food and drug administration (fda).
AQST Ratings Summary
AQST Quant Ranking